Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate.

Greaves, Wayne; Wan, Hong; Yee, Ka Lai; Kandala, Bhargava; Vaddady, Pavan; Hwang, Carey

Greaves, Wayne; Wan, Hong; Yee, Ka Lai; Kandala, Bhargava; Vaddady, Pavan; Hwang, Carey.

Afiliación

Greaves W; Global Clinical Development Infectious Diseases, Merck & Co., Inc., Kenilworth NJ, USA wayne.greaves@merck.com.
Wan H; Biostatistics and Research Decision Sciences, Merck & Co., Inc., Kenilworth NJ, USA.
Yee KL; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth NJ, USA.
Kandala B; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth NJ, USA.
Vaddady P; Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., Kenilworth NJ, USA.
Hwang C; Global Clinical Development Infectious Diseases, Merck & Co., Inc., Kenilworth NJ, USA.

Antimicrob Agents Chemother ; 63(12)2019 09 09.

Article en En | MEDLINE | ID: mdl-31548188

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Antimicrob Agents Chemother Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google